After a year that saw Bothell, WA-based SonoSite partner with ultrasound giant ATL and that saw the company’s flagship product, a handheld digital ultrasound system, purchased by the 19 member countries of NATO for battlefield use
After a year that saw Bothell, WA-based SonoSite partner with ultrasound giant ATL and that saw the companys flagship product, a handheld digital ultrasound system, purchased by the 19 member countries of NATO for battlefield use (SCAN 4/12/00), SonoSite predicted its second-half revenue will not meet analysts expectations.
SonoSite blamed the slump on a physician strike in South Korea and on a hospital market capital freeze in Taiwan. The company said in a statement, however, that U.S. sales are expected to grow.
The 5-pound portable SonoSite 180 system was developed using licensed ATL technology, and part of the SonoSite system is manufactured by ATL, a Philips Medical System company. ATL Ultrasound is able to bundle sales of the handheld SonoSite 180 with its own ultrasound systems.
SonoSite and ATL Ultrasound signed an agreement in March of this year giving ATL exclusive rights to include SonoSites SonoHeart handheld echocardiology device with sales of its own HDI ultrasound systems and with cardiac catheterization systems from Philips Medical Systems.
The SonoHeart is to be launched this month at the Japanese Society of Cardiology meeting in Osaka. The SonoHeart agreement with ATL covers distribution of products in cardiology-related segments worldwide, with the exception of Japan. Distribution in Japan is covered under an agreement with Olympus Optical.
CT Study Reveals Key Indicators for Angiolymphatic Invasion in Non-Small Cell Lung Cancer
January 15th 2025In computed tomography (CT) scans for patients with solid non-small cell lung cancer (NSCLC) < 30 mm, emerging research suggests the lollipop sign is associated with a greater than fourfold likelihood of angiolymphatic invasion.
Can MRI-Based AI Enhance Risk Stratification in Prostate Cancer?
January 13th 2025Employing baseline MRI and clinical data, an emerging deep learning model was 32 percent more likely to predict the progression of low-risk prostate cancer (PCa) to clinically significant prostate cancer (csPCa), according to new research.
Shaping the Future of Radiology in 2025: Trends, Threats, and Opportunities
January 10th 2025How do we respond to challenges with staff recruitment, cybersecurity, and looming hospital takeovers in radiology? This author assesses key trends in radiology and offers key insights to stay competitive in the field.